A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. METHODS: In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent β-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks. The primary end point was the percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval. Other efficacy end points included reductions in the transfusion burden during any 12-week interval and results of iron studies. RESULTS: A total of 224 patients were assigned to the luspatercept group and 112 to the placebo group. Luspatercept or placebo was administered for a median of approximately 64 weeks in both groups. The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001). During any 12-week interval, the percentage of patients who had a reduction in transfusion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage of those who had a reduction of at least 50% (40.2% vs. 6.3%). The least-squares mean difference between the groups in serum ferritin levels at week 48 was -348 μg per liter (95% confidence interval, -517 to -179) in favor of luspatercept. Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more common with luspatercept than placebo. CONCLUSIONS: The percentage of patients with transfusion-dependent β-thalassemia who had a reduction in transfusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led to the discontinuation of treatment. (Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015-003224-31.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
Citations
Cites
Global epidemiology of haemoglobin disorders and derived service indicators
Modell, B. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.06.036673 · Cited by 1,924
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Self-citationWood, J. C., Enriquez, C., Ghugre, N., Tyzka, J. M., Carson, S., Nelson, M. D., & Coates, T. D. (2005) · Blood · doi:10.1182/blood-2004-10-3982 · Cited by 1,045
Self-citationNoninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance
St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P., Olynyk, J. K., Pootrakul, P., Robins, E., & Lindeman, R. (2005) · Blood · doi:10.1182/blood-2004-01-0177 · Cited by 909
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 903
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationSurvival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
Modell, B., Khan, M., & Darlison, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02357-6 · Cited by 583
Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 445
Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.-S., El-Chafic, A.-H., Fasulo, M. R., & Cappellini, M. D. (2010) · Blood · doi:10.1182/blood-2009-09-243154 · Cited by 392
Self-citation
Cited by
Items 101–200 of 337
Clinicopathological characteristics and management of extramedullary hematopoiesis: A review
Gupta, S., Krishnan, A. S., Singh, J., Gupta, A., & Gupta, M. (2022) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2022.11.001 · Cited by 14
Confounding factors in the diagnosis and clinical course of rare congenital hemolytic anemias
Fattizzo, B., Giannotta, J. A., Cecchi, N., & Barcellini, W. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02036-4 · Cited by 14
Aksu, T., & Ünal, Ş. (2021) · Trends in Pediatrics · doi:10.5222/tp.2021.10820 · Cited by 25
Disease burden, management strategies, and unmet needs in α‐thalassemia due to hemoglobin H disease
Lal, A., Viprakasit, V., Vichinsky, E. P., Lai, Y., Lu, M., & Kattamis, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27440 · Cited by 13
Self-citationOriga, R., Gianesin, B., Zappu, A., Denotti, A. R., Giorgio, M. A. D., Sciortino, R., Motta, I., Panzieri, D. L., Rosso, R., Bulla, A., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27758 · Cited by 13
Self-citationTaher, A. T., Viprakasit, V., Kattamis, A., Perrotta, S., Ricchi, P., Porter, J. B., Coates, T. D., Forni, G. L., Musallam, K. M., Esposito, O., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016554 · Cited by 13
“22 In the primary analysis of the BEYOND study in patients with NTDT, a significantly higher proportion of patients treated with luspatercept achieved a hemoglobin increase ≥ 1.0 g/ dL compared with patients receiving placebo, 23 leading to European Medicines Agency approval of luspatercept for the…”
InfluentialSelf-citationChen, N., Kassir, N., Laadem, A., Giuseppi, A. C., Shetty, J. K., Maxwell, S. E., Sriraman, P., Ritland, S., Linde, P. G., Budda, B., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1696 · Cited by 13
Self-citationNoun, P., Ibrahim, A., Hodroj, M. H., Bou‐Fakhredin, R., & Taher, A. T. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1819785 · Cited by 15
Self-citationLuspatercept as Potential Treatment for Congenital Sideroblastic Anemia
Dijck, R. V., Silva, A. M. G., & Rijneveld, A. W. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2216213 · Cited by 13
Recurrent spinal cord compression due to extramedullary hematopoiesis in thalassemia patient
Abbarh, S., Al-Mashdali, A. F., Abdelrazek, M., Gurusamy, V. M., & Yassin, M. A. (2022) · Medicine · doi:10.1097/md.0000000000029334 · Cited by 12
“The primary evidence for the efficacy of luspatercept comes from the BELIEVE trial, published in early 2020.([24]) In that trial, luspatercept significantly reduced transfusion requirements compared with placebo with a reduction in transfusions by one-third and at least 2 units during a 12-week period (71 vs 30 percen…”
BackgroundRise of the planet of rare anemias: An update on emerging treatment strategies
Fattizzo, B., & Motta, I. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1097426 · Cited by 15
“The phase III BELIEVE trial showed that a significantly greater percentage of patients receiving luspatercept achieved the primary endpoint of a ≥33% reduction in transfusion burden from baseline during weeks 13–24, with a reduction of ≥2 RBC units compared with placebo (5).”
BackgroundTeawtrakul, N., Chansai, S., Yamsri, S., Chansung, K., Wanitpongpun, C., Lanamtieng, T., Phiphitaporn, P., Fucharoen, S., & Pongchaiyakul, C. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.05.002 · Cited by 12
Yasara, N., Wickramarathne, N., Mettananda, C. D., Manamperi, A., Premawardhena, A., & Mettananda, S. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041958 · Cited by 12
Hemoglobinopathies and Thalassemias
Peslak, S. A., & Sayani, F. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-812534-2.00009-6 · Cited by 14
Musallam, K. M., Vitrano, A., Inzerillo, A., Maggio, R. D., Barone, R. M. E., Giangreco, A., Renda, M. C., Fecarotta, E., Troia, A., Giambona, A., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70047 · Cited by 12
Self-citationMusallam, K. M., Sheth, S., Cappellini, M. D., Shah, F., Rivella, S., Sankaran, V. G., Kuo, K. H. M., Viprakasit, V., Eleftheriou, A., Angastiniotis, M., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00320-5 · Cited by 11
Self-citationExa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
Frangoul, H., de la Fuente, J., Chopra, Y. R., Meisel, R., Amrolia, P. J., Algeri, M., Sharma, A., Cappellini, M. D., Corbacioglu, S., Kattamis, A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603387 · Cited by 12
Self-citationFunctionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily
Kumar, R., Grinberg, A. V., Li, H., Kuo, T., Sako, D., Krishnan, L., Liharska, K., Li, J., Grenha, R., Maguire, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97203-9 · Cited by 14
Modica, S. M. D., Tanzi, E., Olivari, V., Lidonnici, M. R., Pettinato, M., Pagani, A., Tiboni, F., Furiosi, V., Silvestri, L., Ferrari, G., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26673 · Cited by 12
Farmakis, D. T., Angastiniotis, M., Ghoul, M.-M. E., Cannon, L., & Eleftheriou, A. (2022) · Hemoglobin · doi:10.1080/03630269.2022.2099285 · Cited by 11
Cappellini, M. D., Taher, A. T., Piga, A. G., Shah, F., Voskaridou, E., Viprakasit, V., Porter, J. B., Hermine, O., Neufeld, E. J., Thompson, A. A., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13975 · Cited by 11
“In the BELIEVE trial, luspatercept reduced transfusion burden (frequency of RBCTs) but placebo did not.(14) Therefore, the placebo group was likely to receive a greater RBCT-related HRQoL benefit than patients trea-”
InfluentialSelf-citationMyelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia
Feld, J., Navada, S. C., & Silverman, L. R. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106430 · Cited by 12
The EHA Research Roadmap: Anemias
Iolascon, A., Rivella, S., Anagnou, N. P., Camaschella, C., Swinkels, D. W., Muckenthaler, M. U., Porto, G., Barcellini, W., Andolfo, I., Risitano, A. M., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000607 · Cited by 11
Self-citationKlencke, B. J., Donahue, R. M. J., Gorsh, B., Ellis, C. E., Kawashima, J., & Strouse, B. (2024) · Future Oncology · doi:10.2217/fon-2023-0964 · Cited by 11
Panzieri, D. L., Consonni, D., Scaramellini, N., Ausenda, G., Granata, F., Caponio, N., Duca, L., Leoni, S., Elli, S., Ferraresi, M., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27474 · Cited by 10
Self-citationOriga, R., & Issa, L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226966 · Cited by 13
“Treatment discontinuation due to adverse reactions was observed in 2.6% of patients treated with luspatercept [114].”
InfluentialSelf-citationDelgado, J., Voltz-Girolt, C., Stain, M., Bałkowiec-Iskra, E., Mueller, B., Wernsperger, J., Malinowska, I., Gisselbrecht, C., Enzmann, H. G., & Pignatti, F. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000616 · Cited by 13
Gibson, J. S., & Rees, D. C. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2179484 · Cited by 12
“tion via the SMAD pathway are aimed at this target [185].”
BackgroundChapin, J. C., Cohen, A. R., Neufeld, E. J., Vichinsky, E. P., Giardina, P. J., Boudreaux, J. M., Le, B. C., Kenney, K. M., Trimble, S. R., & Thompson, A. A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17920 · Cited by 11
Self-citationTargets in MPNs and potential therapeutics
Levy, G., Mambet, C., Pecquet, C., Bailly, S., Havelange, V., Diaconu, C. C., & Constantinescu, S. N. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2021.06.004 · Cited by 11
Alashkar, F., Klump, H., Lange, C. P., Proske, P., Schüßler, M., Yamamoto, R., Carpinteiro, A., Berliner, C., Schlosser, T. W., Röth, A., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13849 · Cited by 9
“(NCT02604433), which evaluated the efficacy and safety of luspatercept in adult patients with TDT.(13) In the BEYOND trial (NCT03342404) treatment with luspatercept was associated with an”
Backgroundde la Iglesia, S., Bullón, L. N., Stuckey, R., Vaz, Á. V., Perera, M. D. M., Hernández, M., Pérez, C. S., Sáez-Bravo, M. L., Rodríguez, L. J., Hernández, L. G., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18470 · Cited by 9
Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
Longo, F., Motta, I., Pinto, V. M., Piolatto, A., Ricchi, P., Tartaglione, I., & Origa, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072584 · Cited by 10
“The adverse events with at least 5% higher incidence in the luspatercept group than in the placebo group were bone pain, arthralgia, dizziness, hypertension, and hyperuricemia [4].”
BackgroundSelf-citationPyruvate kinase activators: targeting red cell metabolism in thalassemia
Kuo, K. H. M. (2023) · Hematology · doi:10.1182/hematology.2023000468 · Cited by 9
Self-citationUnmet needs in β-thalassemia and the evolving treatment landscape
Njeim, R., Naouss, B., Bou‐Fakhredin, R., Haddad, A., & Taher, A. T. (2023) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2023.12.003 · Cited by 11
Self-citationWake, M., Palin, A., Belot, A., Berger, M., Lorgouilloux, M., Bichon, M., Papworth, J., Bayliss, L., Grimshaw, B., Rynkiewicz, N. K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012010 · Cited by 12
Guerra, A., Hamilton, N., Rivera, A., Demsko, P., Guo, S., & Rivella, S. (2024) · American Journal of Hematology · doi:10.1002/ajh.27332 · Cited by 10
Swan, J., Szabó, Z., Peters, J., Kummu, O., Kemppi, A., Rahtu‐Korpela, L., Konzack, A., Hakkola, J., Pasternack, A. H., Ritvos, O., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116683 · Cited by 9
Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
Dighriri, I. M., Alrabghi, K. K., Sulaiman, D. M., Alruwaili, A. M., Alanazi, N. S., Al-Sadiq, A.-M. A., Hadadi, A. M., Sahli, B. Y., Qasem, B. A., Alotaibi, M. T., et al. (2022) · Cureus · doi:10.7759/cureus.31570 · Cited by 11
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia
Musallam, K. M., & Taher, A. T. (2024) · Hematology · doi:10.1182/hematology.2024000567 · Cited by 10
Self-citationErythroid Cell Research: 3D Chromatin, Transcription Factors and Beyond
Andrieu‐Soler, C., & Soler, É. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116149 · Cited by 8
New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat
Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26197 · Cited by 8
Therapeutics in paediatric genetic diseases: current and future landscape
Koh, A. L., & Jamuar, S. S. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-376 · Cited by 8
Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
Musallam, K. M., Sheth, S., Cappellini, M. D., Kuo, K. H. M., Kattamis, A., Aydınok, Y., Viprakasit, V., & Taher, A. T. (2025) · HemaSphere · doi:10.1002/hem3.70165 · Cited by 8
Self-citationErythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesis
Hoss, S. E., Lizarralde-Iragorri, M. A., Maciel, T. T., & Hermine, O. (2026) · HemaSphere · doi:10.1002/hem3.70297 · Cited by 9
Self-citation[Chinese guideline for diagnosis and treatment of transfusion dependent β-thalassemia (2022)].
(2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.11.002 · Cited by 7
Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports
Shao, Y., Li, H., Ding, S., & Fu, R. (2024) · Current Research in Translational Medicine · doi:10.1016/j.retram.2024.103438 · Cited by 7
TGF-β inhibition restores hematopoiesis and immune balance via bone marrow EPCs in aplastic anemia
Zhang, X., Guo, L., Wang, Y., Jia, J., Mi, L., Shen, M.-Z., Wang, Z., Zhang, Z., Li, C., Lyu, Z., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01483-4 · Cited by 7
Advancing the care of β-thalassaemia patients with novel therapies.
Bou‐Fakhredin, R., Motta, I., & Cappellini, M. D. (2022) · Blood transfusion · doi:10.2450/2021.0265-21 · Cited by 10
Self-citationMusallam, K. M., Taher, A. T., Kattamis, A., Kuo, K. H. M., Sheth, S., & Cappellini, M. D. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s368584 · Cited by 7
Self-citationCellular and animal models for the investigation of β-thalassemia
Nai, A., Cordero-Sánchez, C., Tanzi, E., Pagani, A., Silvestri, L., & Modica, S. M. D. (2023) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2023.102761 · Cited by 7
Rambaldi, B., Diral, E., Donsante, S., Marzo, N. D., Mottadelli, F., Cardinale, L., Dander, E., Isimbaldi, G., Pioltelli, P. E., Biondi, A., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04306-w · Cited by 7
Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia
Marinacci, L., Simeone, F. J., Lundquist, A. L., Kuter, D. J., & Mahowald, G. K. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc2004991 · Cited by 7
Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?
Longo, F., & Piga, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175119 · Cited by 8
“• Luspatercept has been recently approved for TDT patients in Europe, the United States and other countries [78,79].”
BackgroundSelf-citationTeawtrakul, N., Jetsrisuparb, A., Pongudom, S., Chansung, K., Sirijerachai, C., & Fucharoen, S. (2025) · British Journal of Haematology · doi:10.1111/bjh.20179 · Cited by 6
TGF-β1-triggered maladaptive bone marrow endothelium impedes hematopoietic recovery
Lyu, Z., Shen, M.-Z., Zhang, Y., Gao, H., Mi, L., Chen, Y., Wang, Z., Zhang, X., Chen, D., Zhang, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02429-y · Cited by 7
“Although current TGF-β 1-targeting agents, such as luspatercept (a novel fusion protein that traps TGF-β ligands), are primarily used to enhance late-stage erythroid maturation in MDS and thalassemia, 39 – 41 our clinical trial data underscore their diverse translational relevance.”
The pleiotropic effects of sotatercept
Manzi, G., Maggio, E., Recchioni, T., Adamo, F. I., Caputo, A., Mihai, A., Papa, S., Serino, G., Scoccia, G., Badagliacca, R., et al. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107577 · Cited by 6
SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia
Khan, M. A., & Palmer, J. M. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.09.002 · Cited by 6
Hereditary disorders of ineffective erythropoiesis
King, R. A., & Khoriaty, R. N. (2025) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2025.102910 · Cited by 13
Improving Ineffective Erythropoiesis in Thalassemia: A Hope on the Horizon
Madan, U., Bhasin, H., Dewan, P., & Madan, J. (2021) · Cureus · doi:10.7759/cureus.18502 · Cited by 10
Social Impact and Quality of Life of Patients with β-Thalassaemia: A Systematic Review
Greco, F., & Marino, F. (2022) · EMJ Hematology · doi:10.33590/emjhematol/22-00041 · Cited by 6
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
Cappellini, M. D., Taher, A. T., Verma, A. K., Shah, F., & Hermine, O. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101039 · Cited by 7
Self-citationCauses of Death and Mortality Trends in Individuals with Thalassemia in the United States, 1999-2020
Tan, J. Y., Yeo, Y. H., Chan, K. H., Shaaban, H. S., & Guron, G. K. (2024) · Journal of Blood Medicine · doi:10.2147/jbm.s470177 · Cited by 6
Understanding and targeting erythroid progenitor cells for effective cancer therapy
Wang, Q., Poole, R. A., & Opyrchal, M. (2023) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000762 · Cited by 7
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy
Denton, C. C., Vodala, S., Veluswamy, S., Hofstra, T. C., Coates, T. D., & Wood, J. C. (2023) · Blood · doi:10.1182/blood.2023021839 · Cited by 7
Self-citationPiel, F. B., de Montalembert, M., Das, R., Kuo, K. H. M., Taher, A. T., Musallam, K. M., Treadwell, M. J., Fucharoen, S., Angastiniotis, M., Higgs, D. R., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00722-w · Cited by 5
“%) achieved a ≥33% reduction in transfusion burden from baseline during weeks 13–24 compared with the placebo (4.5%), with higher responses noted in patients with milder genotypes and transfusion burden 166 .”
InfluentialSelf-citationGlobal Trends on β-Thalassemia Research Over 10 Years: A Bibliometric Analysis
Lv, A., Li, J., Chen, M., Wang, W., Xu, L., & Huang, H. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s479493 · Cited by 8
Lv, A., Chen, M., Zhang, S., Zhao, W., Li, J., Lin, S., Zheng, Y., Lin, N., Xu, L., & Huang, H. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13372 · Cited by 6
“Furthermore, it has been demonstrated that the novel activin receptor ligand trap luspatercept improves late‑stage erythropoiesis (9,10). despite the promising nature of these methods, there remain numerous safety concerns including off‑target activity and chromosomal rearrangement events due to…”
Zhang, Z., Wang, L., Liu, Z., Chen, Y., Chen, M., & Han, B. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03141-7 · Cited by 9
Lob, H. E., Singh, N., Mohammadi, K. A., Ivanova, L., Crowell, B., Kim, H. J., Kravets, L., Das, N., Ray, Y., Kim, J. H., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.191813 · Cited by 10
“Eryth-ropoietic stimulating agents such as luspatercept [ACVR2B(L79D)-Fc], can significantly reduce transfusion burden but have not been shown to cause clinically significant liver iron reduction (20, 21).”
Drug safety in thalassemia: lessons from the present and directions for the future
Grech, L., Sultana, J., Borg, K., & Borg, J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1919081 · Cited by 6
Kang, C., & Syed, Y. Y. (2021) · Drugs · doi:10.1007/s40265-021-01527-9 · Cited by 5
“Significantly more luspatercept than placebo recipients in the ITT population achieved the primary endpoint of ≥ 33% reduction from baseline in transfusion burden during weeks 13–24 plus a reduction of ≥ 2 RBC units during the same period (Table 2) [11, 21].”
BackgroundResultInfluentialCurrent and Future Therapies for β-Thalassaemia: A Review Article
Giannoni, L., & Angelucci, E. (2021) · EMJ Hematology · doi:10.33590/emjhematol/20-00249 · Cited by 5
Eleftheriou, A., Antoniou, E., Darbà, J., Ascanio, M., Angastiniotis, M., & Farmakis, D. T. (2022) · Hemoglobin · doi:10.1080/03630269.2023.2167657 · Cited by 8
Novel therapeutics for myelofibrosis
Lee, S. (2023) · Blood Research · doi:10.5045/br.2023.2023012 · Cited by 8
Bruzzese, A., Martino, E. A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Zimbo, A. M., Fragliasso, V., Neri, A., Morabito, F., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2343780 · Cited by 5
Nathan, D. I., Feld, J., Jamal, S. M. E., Mascarenhas, J. O., & Tremblay, D. A. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106820 · Cited by 5
Emerging Therapies in β-Thalassemia
Bou‐Fakhredin, R., Kuo, K. H. M., & Taher, A. T. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.010 · Cited by 6
Self-citationUnplanned pregnancy in women with beta‐thalassaemia treated with luspatercept
Zaccheddu, E., Zappu, A., Barella, S., Clemente, M. G., Orecchia, V., Pilia, M. P., Piras, S., Pitturru, C., Scarano, M., & Origa, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19480 · Cited by 4
Self-citationLuspatercept in Transfusion‐Dependent β‐Thalassemia: The Benefit Is Real, and So Are the Risks
Musallam, K. M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27745 · Cited by 4
Beyond transfusions and transplants: genomic innovations rewriting the narrative of thalassemia
Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06548-y · Cited by 8
“This drug not only significantly and consistently reduces the transfusion burden in TM patients but is also effective for β-thalassemia patients with TDT and NTDT, consistently alleviating anemia symptoms with mild and predictable side effects [60 , 134 ].”
Musallam, K. M., Vitrano, A., Inzerillo, A., Maggio, R. D., Barone, R. M. E., Giangreco, A., Renda, M. C., Fecarotta, E., Troia, A., Giambona, A., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70100 · Cited by 4
Self-citationInhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities
Gao, X., Li, X., Zhang, C., Zhou, J., Gu, K., Liu, X., & Bai, C. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157048 · Cited by 4
Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β‐Thalassemia
Shen, Y., Wei, J., Tang, S., Wu, D., Zong, L., Ma, S., Xiong, Q., Gong, R., Xu, S., Peng, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202513469 · Cited by 4
Coronavirus Disease 2019 in Patients with Thalassemia;Emerging Challenges
Hashemieh, M., & Shirvani, F. (2021) · International journal of pediatrics · doi:10.22038/ijp.2020.53675.4254 · Cited by 4
Beta-thalassemia: is cure still a dream?
Hodroj, M. H., Akiki, N., Bou‐Fakhredin, R., & Taher, A. T. (2023) · Minerva Medica · doi:10.23736/s0026-4806.23.08501-4 · Cited by 5
Self-citationZhang, Z., Hu, Q., Tang, X., Zhang, M., Jinsong, J., Shi, H., Ding, X., Chen, Y., Chen, M., & Han, B. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05334-y · Cited by 6
Beta-Thalassemia: A Pharmacological Drug-Based Treatment
Biswas, S., Smrity, S. Z., Bhuia, M. S., Sonia, F. A., Aktar, A., Chowdhury, R., Islam, T., Islam, M. T., Alencar, G. G., Paulo, C. L. R., et al. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3010008 · Cited by 4
“As a result, it offers a promising treatment option for β -thalassemia-affected individuals who need RBC transfusions regularly [24]. a result, it o ff ers a promising treatment option for β -thalassemia-a ff ected individuals who need RBC transfusions regularly 130 The drug is used to cure anemia in…”
BackgroundZhu, W., He, Y., Huang, M., Fu, S., Liu, Z., Wang, X., Li, Z., Li, X., Chen, J., & Li, Y. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s462991 · Cited by 7
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Xin, X., Zhang, W., Li, Z., Gui, R., Wang, J., Ji, L., Zhang, Y., Fang, B., Song, Y., Zu, Y., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01218-8 · Cited by 4
Patent-paper citations: A window into the technological impact of Tunisian research
Mhamdi, R. (2025) · African Journal of Science Technology Innovation and Development · doi:10.1080/20421338.2024.2433846 · Cited by 5
Highlights on the Luspatercept Treatment in Thalassemia
Aydınok, Y. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13010008 · Cited by 4
“All such events occurred in patients who had undergone splenectomy and had at least one risk factor for thromboembolic disease at baseline [28].”
BackgroundLeoni, S., Bou‐Fakhredin, R., Granata, F., Cassinerio, E., Maggioni, M., Fracanzani, A. L., Cappellini, M. D., & Motta, I. (2024) · Annals of Hematology · doi:10.1007/s00277-023-05591-x · Cited by 4
“Ten days earlier, the patient received the first dose of luspatercept, a novel first-in-class erythroid maturation agent used to treat anemia in adult patients with TDT [8], and 20 days before his admission, he received the first dose of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine.”
Self-citationTanzi, E., Modica, S. M. D., Bordini, J., Olivari, V., Pagani, A., Furiosi, V., Silvestri, L., Campanella, A., & Nai, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27336 · Cited by 5
Introduction to a review series on normal and pathologic erythropoiesis
Cazzola, M. (2022) · Blood · doi:10.1182/blood.2022015497 · Cited by 5
Diagnostik und Therapie der alpha- und beta-Thalassämien
Cario, H. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1767-8379 · Cited by 6
“[15] Cappellini MD, Viprakasit V, Taher AT et al.”
BackgroundInfluentialLuspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
Weidner, H., Wobus, M., Hofbauer, L. C., Rauner, M., & Platzbecker, U. (2022) · Leukemia · doi:10.1038/s41375-022-01702-1 · Cited by 4
“Luspatercept has been demonstrated to improve RBC maturation in murine models and patients with MDS as well as beta-thalassemia [5, 6, 9, 10].”
BackgroundRecent Advances in Thalassemia Management: From Curative Therapies to Artificial Intelligence
Gamaleldin, M. M. A., Abdelhalim, S. M. N. S., & Abraham, I. L. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16020007 · Cited by 3
“Thalidomide use is limited by clinically important toxicities, including sedation, constipation, peripheral neuropathy, and an increased risk of thromboembolic events; hypothyroidism has also been reported [41,42].”
Cappellini, M. D., Sheth, S., Taher, A. T., Al-Samkari, H. T., Antmen, B., Benéitez, D., Cannas, G., Coates, T. D., Czapla, L., Dahlin, J. L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00874-3 · Cited by 4
Self-citationSeijari, M. N., Alshurafa, A., & Yassin, M. A. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8795 · Cited by 3
Metadata
- Authors
- Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., Chew, L.-P., Bee, P.-C., Lim, S.-M., Lu, M.-Y., Tantiworawit, A., Ganeva, P., Gercheva, L., Shah, F., Neufeld, E. J., Thompson, A., Laadem, A., Shetty, J. K., Zou, J., Zhang, J., Miteva, D., Zinger, T., Linde, P. G., Sherman, M. L., Hermine, O., Porter, J., & Piga, A.
- Affiliations
- University of Milan (IT)
- Siriraj Hospital (TH)
- University Health Network (CA)
- University of Southern California (US)
- From the Department of Clinical Sciences and Community, University of Milan, IRCCS Ca’ Granda Foundation Maggiore Policlinico Hospital, Milan (M.D.C.), Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, E.O. Ospedali Galliera, Genoa (G.L.F.), Ospedale Pediatrico Microcitemico A. Cao, Azienda Ospedaliera G. Brotzu, Cagliari (R.O.), Ematologia e Oncologia Pediatrica, Università della Campania L. Vanvitelli, Caserta (S.P.), and the Department of Clinical and Biological...
- University of California, San Francisco (US)
- The University of Sydney (AU)
- University Malaya Medical Centre (MY)
- St. Jude Children's Research Hospital (US)
- Lurie Children's Hospital (US)
- Hôpital Necker-Enfants Malades (FR)
- University College London Hospitals NHS Foundation Trust (GB)
- ORCID
- Cappellini, M. Domenica
- Viprakasit, Vip
- Taher, Ali T.
- Georgiev, Pencho
- Kuo, Kevin H.M.
- Coates, Thomas
- Voskaridou, Ersi
- Perrotta, Silverio
- Lal, Ashutosh
- Kattamis, Antonis
- Vlachaki, Efthymia
- Origa, Raffaella
- Ho, P. Joy
- Bee, Ping-Chong
- Lu, Meng-Yao
- Tantiworawit, Adisak
- Gercheva, Liana
- Shah, Farrukh
- Neufeld, Ellis J.
- Thompson, Alexis
- Laadem, Abderrahmane
- Shetty, Jeevan K.
- Sherman, Matthew L.
- Hermine, Olivier
- Piga, Antonio
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-26
- Volume
- 382
- Issue
- 13
- Pages
- 1219-1231
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3014005795
- Cited by
- 332
- References
- 28
- Citations by year
- 2026: 51 · 2025: 48 · 2024: 57 · 2023: 49 · 2022: 54 · 2021: 52 · 2020: 21
- FWCI
- 22.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Acceleron Pharma
- Celgene
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- transfusion-dependent beta-thalassemia, transfusion burden, erythroid maturation, recombinant fusion protein, serum ferritin, iron overload, adverse events, hyperuricemia, hypertension, bone pain, joint pain, dizziness, best supportive care
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Ferritins, Hematinics, Humans, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Splenectomy, Odds Ratio, Least-Squares Analysis, beta-Thalassemia, Erythrocyte Transfusion, Activin Receptors, Type II, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.